Glintborg D, et al. - An inquiry was set up with regard to the changes in adrenal activity, metabolic status, and mental health in polycystic ovary syndrome (PCOS) during treatment with escitalopram or placebo. In women with PCOS , a rise was noted in the waist circumference and cortisol levels during treatment with escitalopram, with no clinical depression. On the other hand, metabolic risk markers, mental health and health-related quality of life (HRQoL) remained unchanged.